Lunai Bioworks Inc. (LNAI)
| Market Cap | 829.68K -96.6% |
| Revenue (ttm) | 51,992 |
| Net Income | -3.56M |
| EPS | -1.06 |
| Shares Out | 5.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,275,391 |
| Open | 0.2290 |
| Previous Close | 0.2361 |
| Day's Range | 0.1410 - 0.2300 |
| 52-Week Range | 0.1410 - 13.2800 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About LNAI
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and vali... [Read more]
Financial Performance
Financial StatementsNews
Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (Nasdaq: LNAI) (the "Company") announced that on October 21, 2026, it received a letter from the Listing Qualifications Department...
Lunai Bioworks Annual report: Q4 2026
Lunai Bioworks has published its Q4 2026 annual report on October 13, 2026.
Lunai Bioworks expands Parkinson’s platform through agreement with Tanaist
Lunai Bioworks (LNAI) announced an exclusive worldwide license and collaboration agreement with Tanaist that adds human cellular phenotyping to Lunai’s Parkinson’s disease discovery and validation pla...
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets ...
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risks SACRAMENTO, Calif., Sept. 16, 2026 /PRNewswire/ -- Lunai B...
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint
Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker devel...
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del....
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation b...
Lunai Bioworks and BrainStorm launch foundation for neurological diseases
Lunai Bioworks’ (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic ...
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development SACRAMENTO, Calif...
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
WASHINGTON, May 22, 2026 /PRNewswire/ -- On Wednesday, May 20, 2026, a United States District Court Magistrate Judge in Delaware granted the Motion of Lunai Bioworks, Inc. (Nasdaq: LNAI) (Lunai) to co...
Lunai Bioworks Inc. trading halted, news pending
19:50 EDT Lunai Bioworks (LNAI) Inc. trading halted, news pending
Lunai Bioworks announces reverse stock split
Lunai Bioworks (LNAI) announced that it will effect a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-8. The…
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock split of its issued and outstanding common stoc...
Lunai Bioworks Quarterly report: Q3 2026
Lunai Bioworks has published its Q3 2026 quarterly earnings report on May 15, 2026.
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock
WASHINGTON, D.C. , May 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- On Monday, May 11, 2026, national law firms Dickinson Wright and Fox Rothschild joined forces to file a lawsuit on behalf of their firms'...
Lunai Bioworks Transcript: AGM 2026
Shareholders were presented with two proposals: a reverse stock split and potential adjournment to solicit more votes. Both proposals were recommended by the board, and voting was conducted during the meeting.
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications SACRAMENTO, Calif., May 4, 2026 /PRNewswire...
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare...
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Lunai Bioworks Proxy statement: Proxy filing
Lunai Bioworks filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.